

25 During this research, a total of 2,353 patients who were hospitalized children participated.
26 Their ages ranged from under one year old to 18 years old, with females accounting for 43%
27 and males accounting for 57%. The most commonly reported symptom among these patients
28 was fever. The results of the multiplex Real-Time PCR were positive in 8% of cases including;
29 55% COVID-19, 8.5% influenza A, 26% influenza B, and 10.5% co-infections.
30 The results of this study showed that the frequency of seasonal influenza has decreased
31 compared to previous years, which could be due to the improvement of personal protection due
32 to the COVID-19 pandemic. On the other hand, the presence of co-infection in this study is
33 important and this co-infection should be considered in treatment and diagnostic systems in
34 respiratory infection by physicians.

35 **Key words:** COVID-19, influenza, co-infection, multiplex Real- Time PCR

36 **1. Introduction**

37 The emergence of a novel strain of the human coronavirus, known as SARS-CoV-2, and the
38 ensuing COVID-19 pandemic, is having a profound impact on healthcare systems and
39 communities globally (1, 2). With the shared characteristics in the transmission, symptoms,
40 and management of COVID-19 and influenza, it is essential to prioritize the establishment of
41 targeted monitoring, testing, and medical interventions for these respiratory diseases. (3, 4).
42 Furthermore, the transmission of the influenza virus mirrors that of COVID-19 in that it is
43 commonly spread through proximity and inhaling respiratory droplets suspended in the air. (4).
44 The importance of maintaining high standards in the management of influenza cases has been
45 emphasized by the World Health Organization (WHO), particularly as resources and attention
46 are currently being diverted to address the COVID-19 pandemic. (3).
47 Conversely, influenza viruses are recognized as one of the prevailing human pathogens because
48 of their frequent seasonal occurrences and the persistent risk of a worldwide pandemic.
49 Annually, more than 650,000 people succumb to illnesses linked to seasonal influenza across

50 the globe. (5, 6). Health officials within the government have put in place several measures to
51 reduce the spread of COVID-19. This includes educating the public on personal hygiene,
52 enforcing limitations on social gatherings, and shutting down borders. These actions are not
53 only intended to combat the spread of COVID-19 but also to potentially decrease the
54 transmission of other contagious diseases. A recent study has shown the effectiveness of facial
55 masks in lowering the transmission of viral respiratory illnesses, underscoring the significance
56 of these preventative measures in safeguarding public health. (7).

57 However, during the COVID-19 pandemic, there was a surge in infections while the influenza
58 continued to spread. It seems that the actions implemented by public health authorities to
59 combat COVID-19 may have also played a role in reducing the transmission of the influenza
60 in early 2020.(4, 8). Furthermore, studying the medical and demographic attributes of influenza
61 during the COVID-19 pandemic is vital. In addition, it is essential to delve into the latest
62 advancements in point-of-care molecular testing, enabling the simultaneous identification of
63 both influenza and coronaviruses. Moreover, the development of innovative treatments for
64 influenza is crucial. (9). This study aimed to determine the frequency of COVID-19 and
65 influenza semitonally in children with pneumonia symptoms.

66 **2. Materials and Methods**

67 2-1. Samples

68 The research was conducted from December 4, 2022, to August 23, 2023, in Iran.
69 Nasopharyngeal swabs were collected from patients admitted to the Mofid Children's Hospital
70 in Tehran, Iran and suspected of having COVID-19 and/or influenza from various hospital
71 wards. The samples were transported to the Pediatric Infections Research Center (PIRC) by
72 using the standard method of viral transport medium (VTM). Patient demographic information

73 was collected through an information form after obtaining permission from the parents of the
74 children.

75 2-2. Total RNA extraction

76 Following the preparation of the samples, total RNA extraction was conducted using a
77 commercial Viral Nucleic Acid (VNA) Extraction kit (SIMBIOLAB. Lot. No. 010502-2326-
78 202N100) based on silicon column method.

79 2-3. Real-Time PCR

80 Multiplex Real-Time PCR was used for COVID-19 and influenza A and B identification by
81 detection the N gene in corona Virus, M2 and NS1 in influenza A and B, respectively by Viga
82 SARS-COV2 and Influenza A/B multiplex Real-Time PCR kit (ROJE Technology. Lot No.
83 512623082310041). The one-step multiplex Real-Time PCR program was; 50°C for 20 minutes
84 to cDNA synthesis followed by; 95°C for one minute and 45 cycles of; 95°C 10 seconds and
85 55°C for 45 seconds. The process ended by 72°C for 15 seconds.

86 2-4. Data analysis

87 Statistical analysis was done by SPSS software version 23. To determine the relationship
88 between symptoms, gender and age, Real- Time positive results for COVID-19 and/or
89 influenza. The t-test was used. A p value ≤ 0.05 was

90 **3. Results**

91 In the duration of this study, a total of 2,353 individuals who were hospitalized were included
92 in the study. The age of the patients ranged from under one year to 18 years old. Of all the
93 patients, 43% were female and 57% were male. The most common symptom observed in
94 patients was fever, which was linked to respiratory infections. The detailed frequency of
95 symptoms can be found in Table 1.


Table1. frequency of symptoms

Symptoms	Frequency (%)
Fever	20
Cough	12
Respiratory distress	11
Seizure	7
Diarrhea	5
Vomiting	3
Abdominal pain	2
Others such as; chest pain, imbalance and headache, Decreased level of consciousness	40

97

98 Specimens were collected from various departments within the hospital including the
99 emergency room, infectious diseases unit, respiratory ward, pediatric intensive care unit
100 (PICU), neonatal intensive care unit (NICU), and transplant ward. The emergency room and
101 transplant ward had the highest and lowest number of specimens, accounting for 27% and 0.1%
102 of the total samples, respectively.

103 The results of the Real- Time PCR were positive in 303 (12.8%) cases that include; 167 (55%)
104 COVID-19, 26 (8.5%) influenza A, 78 (26%) influenza B and 32 (10.5%) different co-
105 infections. The co-infections were; 28 (87.5%) COVID-19 and influenza B, 2 (6.25%) COVID-
106 19 and influenza A and 2 (6.25%) influenza A and B. All co-infections were observed in under
107 11 years old children and the 66% of them under 6 years old. Also, frequency of co-infections
108 in different seasons shows in figure 1. Also, the symptoms like fever and cough were more
109 observed in co-infection but it did not significant. (p value >0.05).



110

111

figure1. Frequency of co-infection in different seasons

112

113

114

115 **4. Discussion**

116 According to worldwide clinical monitoring, the happening of influenza and respiratory
117 syncytial virus (RSV) decreased during the COVID-19 pandemic (10-12).

118 In a study conducted by Pourmomen et al., and colleagues in 2023, researchers found that
119 among patients showing symptoms of viral respiratory tract infection, the rates of positive
120 Real-Time PCR tests for COVID-19 and influenza A/B were 10.5% and 11%, respectively
121 (13). The results obtained exceed our own, which may be linked to the population under
122 investigation. The research conducted by Pourmomen et al., included participants across all
123 age groups (13) however, the present study focused solely on children. Conversely, the
124 prevalence of influenza B reported in that study (13) is less than that of the present study. This
125 variation could be attributed to the different seasons during which the studies were conducted.

126 It is noteworthy that in the current study, conducted during the spring and summer, the
127 incidence of influenza B was surprisingly higher than that of influenza A.

128 Numerous research studies have shown that the influenza A virus is more widespread compared
129 to other strains of the influenza virus (13-15) The influenza B virus contributes to
130 approximately 25% of the annual influenza cases (13, 16). Influenza B viruses cause fewer and
131 less severe epidemics, possibly because they mainly circulate among humans without a
132 significant animal reservoir (17). Naturally, it is important to highlight that the data in this
133 research pertains to individuals who have been vaccinated against COVID-19. Previous studies
134 on seasonal influenza have shown a greater occurrence of influenza A compared to influenza
135 B, especially in the context of the pandemic and individuals dealing with COVID-19 or
136 receiving the vaccines (13, 16, 17). It is interesting to observe that following these events, there
137 has been a shift in the prevalence of influenza type B being higher than type A in the current
138 study, which is contrary to earlier findings. However, additional research is required to
139 understand the impact of the COVID-19 pandemic and associated factors on such trends. It
140 appears that certain nonpharmaceutical interventions (NPIs) implemented to control COVID-
141 19 have proven to be effective in reducing influenza epidemics as well. The data suggests a
142 significant decrease in the number of influenza cases following the enforcement of public
143 health strategies aimed at controlling COVID-19. On the other hand, the results of this study
144 showed that the symptoms of COVID-19 and influenza are not significantly different, and no
145 distinction can be made between the two diseases based on clinical symptoms. In addition, co-
146 infection by viruses can exist according to the results of this study especially in spring and
147 summer. Some Co-infection with COVID-19 and influenza A virus was reported in Iran, 2020
148 (18). In a systematic review/meta-analysis, COVID-19 and Influenza B co-infection were
149 reported in 51 patients in other countries (19). A study reported 0.5% co-infection of COVID-
150 19 and influenza B in Iran, 2024 (20) but this frequency increased in our study to 9.2%. Since

151 the highest frequency of influenza B virus was in spring and summer and this virus also had
152 the highest share in co-infections, therefore, physicians and health policymakers should
153 consider this increase of influenza B virus after COVID-19 vaccination.

154 **5. Acknowledgment**

155 This study was conducted with the financial support (Grant No. 43008050) with ethical code
156 IR.SBMU.RICH.REC.1402.023, Shahid Beheshti University of Medical Sciences, Tehran,
157 Iran.

158 **6. Authors' contributions**

159 H.Kh, M.A and N.A; laboratory data collection.

160 S.H.A. data gathering.

161 M.E.Y. data extraction from record.

162 F.F. and Sh.A. supervised the study.

163 L.A. designed the study and prepare the manuscript.

164 A.K. clinical consult.

165 H.R. improve the manuscript.

166 **7. Ethics approval and consent to participate**

167 The ethical code of this study is IR.SBMU.RICH.REC.1402.023, Shahid Beheshti University
168 of Medical Sciences, Tehran, Iran. Also, the consent was approved by parents of the children.

169 **8. Availability of data and materials**

170 The data presented in this study are available upon reasonable request from the corresponding
171 author.

172 **9. Competing interests**

173 This study does not have any conflict of interest.

174 **10. Funding**

175 **11. This study does not have any conflict of interest. References**

- 176 1. Azimi L, Karimi A, Alebouyeh M, Shirvani A, Maham S, Rafiei Tabatabaei S, et al. Current
177 Concepts on Immunopathology of COVID-19 and Emerging Therapies. *Arch Pediatr Infect Dis.*
178 2020;8(3):e104266.
- 179 2. Shirvani A, Azimi L, Mansour Ghanaie R, Alebouyeh M, Fallah F, Rafiei Tabatabaei S, et al.
180 Utility of Available Methods for Diagnosing SARS-CoV-2 in Clinical Samples. *Arch Pediatr Infect Dis.*
181 2020;8(3):e103677.
- 182 3. Chotpitayasunondh T, Fischer TK, Heraud JM, Hurt AC, Monto AS, Osterhaus A, et al. Influenza
183 and COVID-19: What does co-existence mean? *Influenza and other respiratory viruses.*
184 2021;15(3):407-12.
- 185 4. Shokri A, Moradi G, Moradpour F, Mohamadi Bolbanabad A, Younesi F, Daftarifard P, et al.
186 Influenza incidence overlapped with COVID-19 or under COVID-19 control measures. *Immunity,*
187 *inflammation and disease.* 2022;10(8):e672.
- 188 5. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of
189 global seasonal influenza-associated respiratory mortality: a modelling study. *Lancet (London,*
190 *England).* 2018;391(10127):1285-300.
- 191 6. Vicari AS, Olson D, Vilajeliu A, Andrus JK, Ropero AM, Morens DM, et al. Seasonal Influenza
192 Prevention and Control Progress in Latin America and the Caribbean in the Context of the Global
193 Influenza Strategy and the COVID-19 Pandemic. *The American journal of tropical medicine and*
194 *hygiene.* 2021;105(1):93-101.
- 195 7. Sohn S, Hong K, Chun BC. Decreased seasonal influenza during the COVID-19 pandemic in
196 temperate countries. *Travel medicine and infectious disease.* 2021;41:102057.
- 197 8. Di Giuseppe G, Pelullo CP, Paolantonio A, Della Polla G, Pavia M. Healthcare Workers'
198 Willingness to Receive Influenza Vaccination in the Context of the COVID-19 Pandemic: A Survey in
199 Southern Italy. *Vaccines.* 2021;9(7).
- 200 9. Sukhdeo S, Lee N. Influenza: clinical aspects, diagnosis, and treatment. *Current opinion in*
201 *pulmonary medicine.* 2022;28(3):199-204.
- 202 10. Ando H, Ahmed W, Iwamoto R, Ando Y, Okabe S, Kitajima M. Impact of the COVID-19
203 pandemic on the prevalence of influenza A and respiratory syncytial viruses elucidated by wastewater-
204 based epidemiology. *The Science of the total environment.* 2023;880:162694.
- 205 11. Casalegno JS, Ploin D, Cantais A, Masson E, Bard E, Valette M, et al. Characteristics of the
206 delayed respiratory syncytial virus epidemic, 2020/2021, Rhône Loire, France. *Euro surveillance :*
207 *bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.*
208 2021;26(29).
- 209 12. Weinberger Opek M, Yeshayahu Y, Glatman-Freedman A, Kaufman Z, Sorek N, Brosh-Nissimov
210 T. Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical
211 distancing measures, Ashdod, Israel, 2021. *Euro surveillance : bulletin Europeen sur les maladies*
212 *transmissibles = European communicable disease bulletin.* 2021;26(29).
- 213 13. Pourmomen M, Younesian O, Hosseinzadeh S, Hosseini Alarzi SS, Pourmomen M, Joshaghani
214 H. Frequency of influenza infection in symptomatic patients suspected of having COVID-19. *Iranian*
215 *Journal of Medical Microbiology.* 2023;17(1):112-6.

- 216 14. Khademi Sayed Bonadaki ZS, Madani R, Pakzad P, Golchinfar F, Emami T. Evaluating the
217 Immunogenicity of Avian Influenza Virus Nucleoprotein. *Iranian Journal of Medical Microbiology*.
218 2020;14(6):643-59.
- 219 15. Javid Khojasteh V, Mojtahedi A, Hosseini S, Joukar F. Relative frequency of influenza A/H1N1
220 virus in Guilan province, Iran. *Iranian Journal of Medical Microbiology*. 2017;11(5):83-9.
- 221 16. Caini S, Kuszniierz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ, et al. The
222 epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st
223 century. *PloS one*. 2019;14(9):e0222381.
- 224 17. Petrova VN, Russell CA. The evolution of seasonal influenza viruses. *Nature reviews*
225 *Microbiology*. 2018;16(1):47-60.
- 226 18. Hashemi SA, Safamanesh S, Ghafouri M, Taghavi MR, Mohajer Zadeh Heydari MS, Namdar
227 Ahmadabad H, et al. Co-infection with COVID-19 and influenza A virus in two died patients with acute
228 respiratory syndrome, Bojnurd, Iran. *Journal of medical virology*. 2020;92(11):2319-21.
- 229 19. Golpour M, Jalali H, Alizadeh-Navaei R, Talarposhti MR, Mousavi T, Ghara AAN. Co-infection
230 of SARS-CoV-2 and influenza A/B among patients with COVID-19: a systematic review and meta-
231 analysis. *BMC infectious diseases*. 2025;25(1):145.
- 232 20. Tarahomi M, Shokri Koohikheyli MS, Pooya P, Eslami M, Vakili M, Habibian F, et al. The
233 Prevalence and Clinical Features of Co-Infection with SARS-CoV-2 and Influenza Virus during the
234 COVID-19 Pandemic in Semnan, Iran. *Medical journal of the Islamic Republic of Iran*. 2024;38:101.

235